Metrics to compare | 493410 | Peers Peers - average of corresponding metrics from companies closely matching 493410: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship493410PeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.2x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 2.8x | |
Upside (Analyst Target) | - | 0.0% | 62.3% | |
Fair Value Upside | Unlock | 0.0% | 8.2% | Unlock |
NEX-I, Inc. develops, manufactures, and markets drugs and immunotherapies for cancer. The company develops Phase 1 products, including NXI-101 and NXI-201, which are monoclonal antibodies, as well as various candidate products, such as NXI-S160, NXI-S301, and NXI-S172, which are antibody-drug conjugates, and NXI-401, a monoclonal antibody drug. It also develops and provides NEXORA, a therapeutics platform; ONCOKINE, a factor associated with resistance to immuno-oncology therapies that suppresses tumor growth and induces immune cell activation in the tumor microenvironment; and SMRT, an immunotherapy in which resistant cancer cells alter the tumor microenvironment into an immunosuppressive state or acquire immune evasion mechanisms through the expression of specific cell surface proteins. The company was founded in 2021 and is headquartered in Seoul, South Korea.